About
About
Biomea Fusion
We are a clinical-stage diabetes and obesity medicines company focused on the development of differentiated oral small molecule therapies, including icovamenib and BMF-650, both being developed to meaningfully improve the lives of patients with metabolic disease. Through our propriety approach , we aim to address the underlying biology of these conditions by targeting key disease-driving mechanisms, with icovamenib focused on delivering durable clinical benefit with the potential to reduce reliance on chronic, lifelong therapy, while BMF-650 is designed for chronic use with a patient-friendly oral profile and manageable titration approach.
Our lead development candidate, icovamenib, is positioned as a potential first-in-class treatment for diabetes. Icovamenib inhibits menin, promoting restoration of insulin-producing beta cells, which are depleted by approximately 50% at the time of diagnosis in type 2 diabetes.1 Functional restoration of this beta cell pool has the potential to drive meaningful and durable glycemic improvements. Icovamenib has also demonstrated synergistic effects when combined with a GLP-1-RA-based therapy, supporting enhanced glycemic control and weight reduction, along with preservation of lean muscle mass.
Our second development candidate, BMF-650, is a next-generation oral GLP-1 receptor agonist aligned with the orforglipron chemotype class, optimized for improved bioavailability, consistent exposure and improved tolerability, with the goal of delivering scalable weight reduction.
With these programs, we are focused on addressing metabolic disorders, a significant and growing public health concern impacting approximately 50% of Americans and 20% of the world’s population. We aim to cure.
Our Focus
- Advancing approaches in diabetes that target underlying biology through beta cell restoration.
- Improving patient experience and long-term persistence in obesity treatment.
- Developing oral medicines designed for accessibility and scalability.
- Retaining global rights across our programs to maximize long-term value
Reference: 1 Diabet Med 1988; 5 :36 –41
Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We came together after a career in drug design and development with the common goal of achieving better therapies for patients.
